Google API keys for services like Maps embedded in accessible client-side code could be used to authenticate to the Gemini AI assistant and access private data. Researchers found nearly 3,000 such ...

Eikon Therapeutics, Inc. (Nasdaq: EIKN), a California-based, late-stage biotechnology company, visits the Nasdaq MarketSite in Times Square. Eikon is led by executive and clinical teams behind the ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

Biotechnology companies going public this week are signaling a resurgence for initial public offerings and venture-capital investment in the sector this year. Biotechs Eikon Therapeutics and ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

Eikon Therapeutics raised an upsized US$381m late Wednesday from its Nasdaq IPO that included participation by Merck, a banker involved in the offering told IFR. The banks were multiple times ...